null

null

Based on the provided description, Athira Pharma, Inc. (trading under the symbol LONA), which you've referred to as LeonaBio, is a late clinical-stage biopharmaceutical company. This means it is primarily focused on the research and development of drug candidates and is conducting clinical trials (Phase 2 and Phase 3 for ATH-1017, and preclinical for other candidates).

At this stage, Athira Pharma, Inc. does not have major customers in the traditional sense, as it is not yet selling any approved products to individuals or other companies. Its primary activities revolve around drug development, rather than commercial sales.

null

The search results provide the current management team for LeonaBio (LONA), formerly Athira Pharma. Result "About – LeonaBio" lists the senior management. Result "LeonaBio, Inc. (LONA) Leadership & Management Team Analysis - Simply Wall St" also lists Mark Litton as CEO. Result "Mark Litton – Athira Pharma" provides a detailed background for Mark Litton. Result "LeonaBio appoints Mark Kubik as chief business officer - Investing.com" and, mention the recent appointment of Mark Kubik. However, the request explicitly asks for "up to 5 management members" and the "About - LeonaBio" page lists 5 senior management members, including the CEO and CFO. Mark Kubik's role is Chief Business Officer, and he has just been appointed as of Feb 3, 2026. I should prioritize the existing listed senior management from the company's own "About" page, if available, and then check other sources for recent updates if needed. The "About - LeonaBio" page appears to be the most current. From "About – LeonaBio": * Mark Litton, PhD. President & Chief Executive Officer * Javier San Martin, M.D. Chief Medical Officer * Kevin Church, PhD. Chief Scientific Officer * Mark Worthington, JD General Counsel, Chief Compliance Officer, & Corporate Secretary * Robert Renninger Chief Financial Officer Now I need to gather background information for these individuals, especially the CEO and CFO, focusing on the requested details: if the CEO or CFO founded or managed other companies, if the CEO or CFO sold companies they were previously involved with to an acquirer, if the CEO or CFO have a pattern of managing companies backed by private equity firms. Let's start with Mark Litton (CEO) and Robert Renninger (CFO). **Mark Litton, PhD. President & Chief Executive Officer** * **Background:** Mark Litton became President and CEO of Athira Pharma (now LeonaBio) in October 2021, and previously served as COO since July 2019. Before Athira, he was President and COO of Alpine Immune Sciences, Inc.. Prior to that, he spent over 14 years at Alder Biopharmaceutical Inc., a publicly traded biopharmaceutical company, which was acquired by Lundbeck A/S. As co-founder and Chief Business Officer (CBO) at Alder, he helped build the business and oversaw finance, investor relations, deal making, business development, alliance management, human resources, and overall corporate strategy. He was responsible for raising over $1 billion in equity capital and led negotiations for numerous corporate alliances. **Robert Renninger. Chief Financial Officer** I need to find background information for Robert Renninger. Let's search for "Robert Renninger LeonaBio CFO background" or "Robert Renninger Athira Pharma CFO background". Since the company name changed recently, searching for "Athira Pharma CFO" might still bring up relevant information.

The key risks to LeonaBio (LONA) are primarily associated with its status as a late clinical-stage biopharmaceutical company focused on developing novel therapeutics.

1. Clinical Trial Outcomes and Regulatory Approval: As a late clinical-stage biopharmaceutical company, LeonaBio's future largely depends on the successful outcome of its clinical trials and the subsequent receipt of regulatory approvals. The company's lead product candidate, ATH-1017, is currently in Phase 3 and Phase 2 clinical trials for Alzheimer's disease and Phase 2 trials for Parkinson's disease. Failure to demonstrate sufficient efficacy and safety in these trials, or the inability to secure regulatory approval from health authorities, would severely impact the company's ability to commercialize its products and generate revenue.
2. Reliance on a Limited Product Pipeline: LeonaBio's pipeline is concentrated on a few key product candidates, with ATH-1017 being the most advanced. While it also has ATH-1019 and ATH-1020 in preclinical stages, a significant portion of its value is tied to the success of ATH-1017. If this lead candidate encounters setbacks or fails in trials, the company has limited other late-stage assets to fall back on, which could have a substantial negative effect on its business and financial health.
3. Intense Competition: The therapeutic areas of Alzheimer's and Parkinson's disease are characterized by significant unmet medical needs and intense competition. Numerous larger pharmaceutical companies and other biotechnology firms are actively researching and developing treatments for these conditions. LeonaBio faces the risk that competitors may develop more effective, safer, or more affordable therapies, or bring their products to market sooner, thereby diminishing the potential market share and profitability of LeonaBio's product candidates if they are approved.

null

null

Expected Drivers of Future Revenue Growth for LeonaBio (LONA)

Over the next two to three years, LeonaBio (LONA), formerly Athira Pharma, Inc., is expected to drive future revenue growth through the following key areas:

1. Advancement and Potential Commercialization of ATH-1017: LeonaBio's lead product candidate, ATH-1017, is currently undergoing Phase 3 (LIFT-AD) and Phase 2 (ACT-AD) clinical trials for Alzheimer's disease, as well as Phase 2 clinical trials for Parkinson's disease. Successful completion of these trials, followed by regulatory approval and market launch, would represent a significant driver of product revenue.
2. Progression and Potential Commercialization of Lasofoxifene: The company is engaged in a Phase 3 development program for lasofoxifene, targeting ER+, HER2-negative, ESR1-mutated metastatic breast cancer. This program has been identified as a potential multi-billion dollar opportunity, with its advancement towards commercialization poised to generate substantial revenue.
3. Development of ATH-1105 for Amyotrophic Lateral Sclerosis (ALS): Following positive results from a Phase 1 clinical study in healthy volunteers, LeonaBio is preparing to begin dosing ALS patients with ATH-1105 in late 2025. Continued successful clinical development of ATH-1105 could lead to future product sales or strategic partnership agreements, contributing to revenue growth.
4. Strategic Partnerships and Licensing Agreements: As a clinical-stage biopharmaceutical company, LeonaBio's revenue growth can be significantly influenced by new or expanded strategic collaborations and licensing agreements for its pipeline assets. Such partnerships often include upfront payments, milestone payments upon achieving developmental or regulatory targets, and future royalties from commercialized products.
5. Expansion and Advancement of Preclinical Pipeline: The progression of preclinical candidates, such as ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions, could, within the 2-3 year timeframe, attract partnership interest or enter early-stage clinical trials. This would establish the foundation for longer-term revenue streams through future development and potential commercialization.

Outbound Investments

• Acquired rights for the development and commercialization of Lasofoxifene from Sermonix Pharmaceuticals through a Corporate Asset Purchase on December 18, 2025.
• Entered into a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa.

Capital Expenditures

• Invested $0 in capital expenditures in Q3 2024.